Quick Answer
Skye Bioscience, Inc. reported Research And Development Expense of $6.01 million for the year ending 2022.
- Skye Bioscience, Inc. showed an increase of +105.1% in Research And Development Expense from 2021 to 2022.
- This data is from Skye Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2023.
- XBRL data for this metric is available from 2014 to 2022 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $195.0 thousand | Q1 2015: $37.2 thousand | Q2 2015: $43.4 thousand | Q3 2015: $152.3 thousand | Q1 2016: $135.4 thousand | Q2 2016: $460.0 thousand | Q3 2016: $80.5 thousand | Q1 2017: $92.1 thousand | Q2 2017: $60.7 thousand | Q3 2017: $88.6 thousand | Q1 2018: $25.0 thousand | Q3 2018: $67.3 thousand | Q1 2019: $321.0 thousand | Q2 2019: $688.0 thousand | Q3 2019: $513.0 thousand | Q1 2020: $799.6 thousand | Q2 2020: $428.5 thousand | Q3 2020: $346.2 thousand | Q1 2021: $609.7 thousand | Q2 2021: $880.7 thousand | Q3 2021: $327.7 thousand | Q1 2022: $1.27 million | Q2 2022: $1.43 million | Q3 2022: $1.78 million | Q1 2023: $1.18 million | Q2 2023: $1.79 million.
- Over the full 9 years of available data (2014 to 2022), Skye Bioscience, Inc.'s Research And Development Expense has grown by 2,542.6%.
- Historical annual values: Fiscal year 2022: $6.01 million | Fiscal year 2021: $2.93 million | Fiscal year 2020: $1.94 million | Fiscal year 2019: $2.24 million | Fiscal year 2018: $330.0 thousand | Fiscal year 2017: $311.3 thousand | Fiscal year 2016: $939.0 thousand | Fiscal year 2015: $576.1 thousand | Fiscal year 2014: $227.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: